Publication | Open Access
Use, access, and initial outcomes of off-label ivosidenib in patients with IDH1 mutant glioma
19
Citations
10
References
2023
Year
Targeted therapies like IVO are options for mIDH glioma patients and can provide positive oncologic and neurological outcomes.
| Year | Citations | |
|---|---|---|
Page 1
Page 1